Gene Predictis
About Gene Predictis
Gene Predictis is a Healthcare company based in Lausanne (Switzerland), and was acquired by NIMGenetics in February 2023. Genomic tests are developed for personalized medicine risks. Its focus areas include Diversified Diagnostics, Life Sciences, Clinical Genomics and Sequencing Based.
Company details
Based in Lausanne, Switzerland, Gene Predictis operates in the genomics sector, where tests for personalized medicine are developed. Focus is placed on screening for disease development risks and adverse drug reactions. Products encompass predictions for overall drug sensitivities, including irinotecan, carbamazepine, clopidogrel, and others, alongside nutrigenomics and inherited factors. Inherited risk tests cover thrombosis, cardiovascular conditions, deep-vein thrombosis, pulmonary embolism, osteoporosis, and further areas like auto-immune diseases and intolerances.
- Headquarters Lausanne, Switzerland
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website genepredictis.com
- Acquired by NIMGenetics (Feb 2023)
- Investors
- Acquired byNIMGenetics
(Feb 2023)
Investors in Gene Predictis
Gene Predictis has secured backing from 1 investor. Prominent investors backing the company include NIMGenetics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diagnostic solutions are developed using microarray and next-generation sequencing technologies. | 2007 | nimgenetics.com | Madrid, Spain |
Investor details for Gene Predictis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Web traffic of Gene Predictis
Websites that share an audience with Gene Predictis (genepredictis.com).
Websites whose visitors overlap most with Gene Predictis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| universite-lyon.fr | 100% | 73.5K | #507,822 | View details | |
gurufi.com | gurufi.com | 100% | – | ||
| imina.ch | 100% | 1.3K | #12,028,535 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gene Predictis
Complete news archive for Gene Predictis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gene Predictis
Gene Predictis is headquartered in Lausanne, Switzerland. It is registered at Lausanne, Vaud, Switzerland.
Based in Lausanne, Switzerland, Gene Predictis operates in the genomics sector, where tests for personalized medicine are developed. Focus is placed on screening for disease development risks and adverse drug reactions. Products encompass predictions for overall drug sensitivities, including irinotecan, carbamazepine, clopidogrel, and others, alongside nutrigenomics and inherited factors. Inherited risk tests cover thrombosis, cardiovascular conditions, deep-vein thrombosis, pulmonary embolism, osteoporosis, and further areas like auto-immune diseases and intolerances.
Gene Predictis has 1 investor. Key investors include NIMGenetics.
Yes. Gene Predictis was acquired by NIMGenetics in February 2023.